Global Statistics Representing Anti-Osteoporosis Therapy and Fracture Healing Market Scenario
Osteoporosis therapy is commonly occurs diseases due to bone mineral density which causes heavy risk of fractures and bone fragility. Mostly fracture occurs in hip, spine, shoulder and forearm. The diagnostic segment is leading include X-ray and radiography tests in anti-osteoporosis therapy.
According to the International Osteoporosis Foundation (IOF), in 2015, one in two women and one in five men aged above 50 years suffered from osteoporosis-related fracture across the globe. Osteoporosis is common disorder in women, after menopause risk of osteoporosis and other calcium deficiency diseases increases significantly. Approximately 158 million people were at high risk of fracture in 2010 and the number is expected to rise to 319 million by 2040.
Anti-osteoporosis therapy has lots of side effects and success rate of the therapy is very low are restrains the growth of market.
The global anti-osteoporosis therapy and fracture healing market accounted for over USD 22,400 million in 2017 and is expected to grow at a CAGR of 8.4 % during the forecast period, 2019-2026.
The global anti-osteoporosis therapy and fracture healing market is segmented by route of administration and drug type.
On the basis of route of administration, the market is segmented into oral and injectable. Oral is leading segment over the forecast period. Most of the drug of this therapy are available in oral form and oral dosage form is cost effective.
Based on drug type, the market is segmented into bisphosphonates and selective estrogen receptor modules. Bisphosphonates segment is expected to be the fastest growing segment throughout the forecast period.
Geographically, the global anti-osteoporosis therapy and fracture healing market is segmented into North America, Europe, Asia pacific, and Latin America and the Middle East & Africa (LAMEA).
North America is likely to hold the major market share during forecast period 2019–2026. According to the International Osteoporosis Foundation (IOF), in 2014, approximately 54% of postmenopausal women were osteopenic and 30% were osteoporotic in the U.S. Osteoporosis is common problem due to which bones become weaker and there is a higher risk of a fracture during a fall or even a fairly minor knock.
Europe is expected to experience significant growth in the anti-osteoporosis therapy and fracture healing market over the forecast period 2019–2026. High prevalence of osteoporosis due to physical inactivity and rising obese population is likely to support the market growth. Changing eating habits and poor nutrition leads to calcium deficiency and different bone diseases which in turn is likely to fuel the market growth.
Asia pacific is expected to be the fastest growing market during the during forecast period 2019–2026. Every year in India around 10 million people experience fractures due to osteoporosis. Furthermore, high prevalence of back pain in women after menopause is likely to support the market growth. Furthermore, growing incidences of calcium deficiency In Japan is propelling the market growth.
Latin America accounts for least share of the global anti-osteoporosis therapy and fracture healing market. Increasing number of incidence of osteoporosis in Mexico, Brazil, Argentina, Bolivia, Puerto Rico and Colombia is expected to influence the market growth. In the Middle East and Africa growing population, and rise in per capita income is driving the market.
Some of the major players in anti-osteoporosis therapy and fracture healing market are F.Hoffmann La Roche Ltd.,Actavis plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Merck and Company Inc., Amgen Inc., Novartis International AG., Pfizer, Inc., and GlaxoSmithKline plc.
Anti-osteoporosis Therapy and Fracture Healing Market Segmentation
By Route of Administration
By Drug Type
Why Buy This Report?